KRAS and adenocarcinoma: The rate of KRAS mutation (2/8) is consistent with the rate of KRAS mutation found in adenocarcinomas in our institution.[31] Only 1/10 had EGFR mutation, which is also in keeping with the expected rate.[32] However interpretation of this data is limited by the small number of cases with molecular markers performed.